Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome
Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was reco...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1988 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: European journal of clinical pharmacology - 1968, 33(1988) vom: Juni, Seite 571-575 |
| Übergeordnetes Werk: |
volume:33 ; year:1988 ; month:06 ; pages:571-575 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202452131 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202452131 | ||
| 003 | DE-627 | ||
| 005 | 20230506081801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1988 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202452131 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| 264 | 1 | |c 1988 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Lanfranchi, G. A. |4 oth | |
| 700 | 1 | |a Bazzocchi, G. |4 oth | |
| 700 | 1 | |a Campieri, M. |4 oth | |
| 700 | 1 | |a Brignola, C. |4 oth | |
| 700 | 1 | |a Fois, F. |4 oth | |
| 700 | 1 | |a Imbimbo, B. P. |4 oth | |
| 773 | 0 | 8 | |i in |t European journal of clinical pharmacology |d 1968 |g 33(1988) vom: Juni, Seite 571-575 |w (DE-627)NLEJ188986677 |w (DE-600)1459058-x |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:1988 |g month:06 |g pages:571-575 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00542489 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 1988 |c 6 |h 571-575 |g 5 | ||
| matchkey_str |
article:14321041:1988----::eutobcmtoimrmdoteooimtrepneoaignainsi |
|---|---|
| hierarchy_sort_str |
1988 |
| publishDate |
1988 |
| allfields |
(DE-627)NLEJ202452131 DE-627 ger DE-627 rakwb eng Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. Springer Online Journal Archives 1860-2002 Lanfranchi, G. A. oth Bazzocchi, G. oth Campieri, M. oth Brignola, C. oth Fois, F. oth Imbimbo, B. P. oth in European journal of clinical pharmacology 1968 33(1988) vom: Juni, Seite 571-575 (DE-627)NLEJ188986677 (DE-600)1459058-x 1432-1041 nnns volume:33 year:1988 month:06 pages:571-575 extent:5 http://dx.doi.org/10.1007/BF00542489 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 33 1988 6 571-575 5 |
| spelling |
(DE-627)NLEJ202452131 DE-627 ger DE-627 rakwb eng Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. Springer Online Journal Archives 1860-2002 Lanfranchi, G. A. oth Bazzocchi, G. oth Campieri, M. oth Brignola, C. oth Fois, F. oth Imbimbo, B. P. oth in European journal of clinical pharmacology 1968 33(1988) vom: Juni, Seite 571-575 (DE-627)NLEJ188986677 (DE-600)1459058-x 1432-1041 nnns volume:33 year:1988 month:06 pages:571-575 extent:5 http://dx.doi.org/10.1007/BF00542489 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 33 1988 6 571-575 5 |
| allfields_unstemmed |
(DE-627)NLEJ202452131 DE-627 ger DE-627 rakwb eng Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. Springer Online Journal Archives 1860-2002 Lanfranchi, G. A. oth Bazzocchi, G. oth Campieri, M. oth Brignola, C. oth Fois, F. oth Imbimbo, B. P. oth in European journal of clinical pharmacology 1968 33(1988) vom: Juni, Seite 571-575 (DE-627)NLEJ188986677 (DE-600)1459058-x 1432-1041 nnns volume:33 year:1988 month:06 pages:571-575 extent:5 http://dx.doi.org/10.1007/BF00542489 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 33 1988 6 571-575 5 |
| allfieldsGer |
(DE-627)NLEJ202452131 DE-627 ger DE-627 rakwb eng Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. Springer Online Journal Archives 1860-2002 Lanfranchi, G. A. oth Bazzocchi, G. oth Campieri, M. oth Brignola, C. oth Fois, F. oth Imbimbo, B. P. oth in European journal of clinical pharmacology 1968 33(1988) vom: Juni, Seite 571-575 (DE-627)NLEJ188986677 (DE-600)1459058-x 1432-1041 nnns volume:33 year:1988 month:06 pages:571-575 extent:5 http://dx.doi.org/10.1007/BF00542489 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 33 1988 6 571-575 5 |
| allfieldsSound |
(DE-627)NLEJ202452131 DE-627 ger DE-627 rakwb eng Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome 1988 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. Springer Online Journal Archives 1860-2002 Lanfranchi, G. A. oth Bazzocchi, G. oth Campieri, M. oth Brignola, C. oth Fois, F. oth Imbimbo, B. P. oth in European journal of clinical pharmacology 1968 33(1988) vom: Juni, Seite 571-575 (DE-627)NLEJ188986677 (DE-600)1459058-x 1432-1041 nnns volume:33 year:1988 month:06 pages:571-575 extent:5 http://dx.doi.org/10.1007/BF00542489 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 33 1988 6 571-575 5 |
| language |
English |
| source |
in European journal of clinical pharmacology 33(1988) vom: Juni, Seite 571-575 volume:33 year:1988 month:06 pages:571-575 extent:5 |
| sourceStr |
in European journal of clinical pharmacology 33(1988) vom: Juni, Seite 571-575 volume:33 year:1988 month:06 pages:571-575 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
European journal of clinical pharmacology |
| authorswithroles_txt_mv |
Lanfranchi, G. A. @@oth@@ Bazzocchi, G. @@oth@@ Campieri, M. @@oth@@ Brignola, C. @@oth@@ Fois, F. @@oth@@ Imbimbo, B. P. @@oth@@ |
| publishDateDaySort_date |
1988-06-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188986677 |
| id |
NLEJ202452131 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202452131</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506081801.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1988 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202452131</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1988</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lanfranchi, G. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bazzocchi, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campieri, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brignola, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fois, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imbimbo, B. P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">European journal of clinical pharmacology</subfield><subfield code="d">1968</subfield><subfield code="g">33(1988) vom: Juni, Seite 571-575</subfield><subfield code="w">(DE-627)NLEJ188986677</subfield><subfield code="w">(DE-600)1459058-x</subfield><subfield code="x">1432-1041</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:1988</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:571-575</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00542489</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">1988</subfield><subfield code="c">6</subfield><subfield code="h">571-575</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188986677 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-1041 |
| topic_title |
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g a l ga gal g b gb m c mc c b cb f f ff b p i bp bpi |
| hierarchy_parent_title |
European journal of clinical pharmacology |
| hierarchy_parent_id |
NLEJ188986677 |
| hierarchy_top_title |
European journal of clinical pharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188986677 (DE-600)1459058-x |
| title |
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| spellingShingle |
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| ctrlnum |
(DE-627)NLEJ202452131 |
| title_full |
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| journal |
European journal of clinical pharmacology |
| journalStr |
European journal of clinical pharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1988 |
| contenttype_str_mv |
zzz |
| container_start_page |
571 |
| container_volume |
33 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| title_auth |
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| abstract |
Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. |
| abstractGer |
Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. |
| abstract_unstemmed |
Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome |
| url |
http://dx.doi.org/10.1007/BF00542489 |
| remote_bool |
true |
| author2 |
Lanfranchi, G. A. Bazzocchi, G. Campieri, M. Brignola, C. Fois, F. Imbimbo, B. P. |
| author2Str |
Lanfranchi, G. A. Bazzocchi, G. Campieri, M. Brignola, C. Fois, F. Imbimbo, B. P. |
| ppnlink |
NLEJ188986677 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| up_date |
2024-07-06T07:56:57.049Z |
| _version_ |
1803815608175820800 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202452131</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506081801.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1988 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202452131</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1988</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10–20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p<0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lanfranchi, G. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bazzocchi, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campieri, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brignola, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fois, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Imbimbo, B. P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">European journal of clinical pharmacology</subfield><subfield code="d">1968</subfield><subfield code="g">33(1988) vom: Juni, Seite 571-575</subfield><subfield code="w">(DE-627)NLEJ188986677</subfield><subfield code="w">(DE-600)1459058-x</subfield><subfield code="x">1432-1041</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:1988</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:571-575</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00542489</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">1988</subfield><subfield code="c">6</subfield><subfield code="h">571-575</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.3987503 |